Indole and benzimidazole derivatives as dual 5-HT2A and 5-HT6 receptor antagonists

1. A compound of general formula (I)

or a pharmaceutically acceptable salt thereof, wherein:

G is CH or N;

R l is H, C 1 -C 4 -alkyl, HO—C 1 -C 4 -alkyl or C 1 -C 4 -alkyl-O—C 1 -C 4 -alkyl;

R 2 is selected from group consisting of:

phenyl group unsubstituted or substituted with at least one substituent, or

5- or 6-membered heteroaryl group unsubstituted or substituted with at least one substituent,

wherein the substituent is selected from F, Cl, Br, C 1 -C 4 -alkyl-, C 1 -C 4 -alkyl-O—.

2. Compound of claim 1 , wherein

G is CH.

3. Compound of claim 1 , wherein

G is N.

4. Compound of claim 1 , wherein

R l is H, methyl, or 2-hydroxyethyl.

5. Compound of claim 1 , wherein

R 2 is selected from phenyl group unsubstituted or substituted with at least one substituent.

6. Compound of claim 1 , wherein

R 2 is selected from 5- or 6-membered heteroaryl group unsubstituted or substituted with at least one substituent.

7. Compound of claim 6 , wherein

5- or 6-membered heteroaryl is selected from furyl, thienyl, thiazolyl, or pyridyl.

8. Compound of claim 1 , wherein

R 2 is selected from group consisting of:

phenyl group unsubstituted or substituted with at least one substituent, or

5- or 6-membered heteroaryl group unsubstituted or substituted with at least one substituent,

wherein 5- or 6-membered heteroaryl is selected from furyl, thienyl, thiazolyl, or pyridyl

wherein the substituent is selected from F, Cl, Br, C 1 -C 4 -alkyl—, C 1 -C 4 -alkyl-O—.

9. The compound of claim 5 wherein the substituent is selected from F, Cl, methyl or methoxy.

10. The compound of formula (I) of claim 1 selected from the group consisting of the following:

1-benzyl-4-(piperazin-1-yl)-2-(trifluoromethyl)-1H-benzimidazole

1-benzyl-4-(4-methylpiperazin-1-yl)-2-(trifluoromethyl)-1H-benzimidazole

2-{4-[1-benzyl-2-(trifluoromethyl)-1H-benzimidazol-4-yl]piperazin-1-yl)ethanol

1-(furan-2-ylmethyl)-4-(piperazin-1-yl)-2-(trifluoromethyl)-1H-benzimidazole

1-[(5-methylfuran-2-yl)methyl]-4-(piperazin-1-yl)-2-(trifluoromethyl)-1H-benzimidazole

1-(3-chlorobenzyl)-4-(piperazin-1-yl)-2-(trifluoromethyl)-1H-benzimidazole

1-(3-fluorobenzyl)-4-(piperazin-1-yl)-2-(trifluoromethyl)-1H-benzimidazole

1-(3,4-dichlorobenzyl)-4-(piperazin-1-yl)-2-(trifluoromethyl)-1H-benzo[d]imidazole

1-(3-chloro-4-fluorobenzyl)-4-(piperazin-1-yl)-2-(trifluoromethyl)-1H-benzo[d]imidazole

1-(3,4-difluorobenzyl)-4-(piperazin-1-yl)-2-(trifluoromethyl)-1H-benzo[d]imidazole

1-(3,5-dichlorobenzyl)-4-(piperazin-1-yl)-2-(trifluoromethyl)-1H-benzo[d]imidazole

1-benzyl-4-(piperazin-1-yl)-2-(trifluoromethyl)-1H-indole

1-(3,4-dichlorobenzyl)-4-(4-methylpiperazin-1-yl)-2-(trifluoromethyl)-1H-indole

1-(4-chloro-3-fluorobenzyl)-4-(4-methylpiperazin-1-yl)-2-(trifluoromethyl)-1H-indole

4-(piperazin-1-yl)-1-(1,3-thiazol-2-ylmethyl)-2-(trifluoromethyl)-1H-indole

1-(4-chloro-3-fluorobenzyl)-4-(piperazin-1-yl)-2-(trifluoromethyl)-1H-indole

1-(furan-2-ylmethyl)-4-(piperazin-1-yl)-2-(trifluoromethyl)-1H-indole

1-(3-methoxybenzyl)-4-(4-methylpiperazin-1-yl)-2-(trifluoromethyl)-1H-indole

1-(3-fluorobenzyl)-4-(piperazin-1-yl)-2-(trifluoromethyl)-1H-indole

1-(3-chloroobenzyl)-4-(piperazin-1-yl)-2-(trifluoromethyl)-1H-indole

1-(furan-2-ylmethyl)-4-(4-methylpiperazin-1-yl)-2-(trifluoromethyl)-1H-indole

1-(3,4-difluorobenzyl)-4-(4-methylpiperazin-1-yl)-2-(trifluoromethyl)-1H-indole

1-(3-methoxybenzyl)-4-(piperazin-1-yl)-2-(trifluoromethyl)-1H-indole

1-(3-fluorobenzyl)-4-(4-methylpiperazin-1-yl)-2-(trifluoromethyl)-1H-indole

1-(3,4-difluorobenzyl)-4-(piperazin-1-yl)-2-(trifluoromethyl)-1H-indole

1-benzyl-4-(4-methylpiperazin-1-yl)-2-(trifluoromethyl)-1H-indole

1-(3-chlorobenzyl)-4-(4-methylpiperazin-1-yl)-2-(trifluoromethyl)-1H-indole

1-[(5-methylfuran-2-yl)methyl]-4-(piperazin-1-yl)-2-(trifluoromethyl)-1H-indole

1-[(5-methylthiophen-2-yl)methyl]-4-(piperazin-1-yl)-2-(trifluoromethyl)-1H-indole

4-(piperazin-1-yl)-1-(thiophen-2-ylmethyl)-2-(trifluoromethyl)-1H-indole

4-(piperazin-1-yl)-1-(thiophen-3-ylmethyl)-2-(trifluoromethyl)-1H-indole

4-(4-methylpiperazin-1-yl)-1-(thiophen-3-ylmethyl)-2-(trifluoromethyl)-1H-indole

4-(4-methylpiperazin-1-yl)-1-(thiophen-2-ylmethyl)-2-(trifluoromethyl)-1H-indole

4-(4-methylpiperazin-1-yl)-1-[(5-methyl-1,3-thiazol-2-yl)methyl]-2-(trifluoromethyl)-1H-indole, and pharmaceutically acceptable salt thereof.

11. The compound of formula (I) of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

12. The compound of formula (I) of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

13. The compound of formula (I) of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

14. The compound of formula (I) of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

15. A pharmaceutical composition comprising a compound of formula (I) or a salt thereof as defined in claim 1 and at least one pharmaceutically acceptable excipient.

16. A method for treatment of a subject afflicted with Alzheimer's disease, Parkinson's disease, Lewy body dementia, dementia-related psychosis, schizophrenia, delusional syndromes and other psychotic conditions related and not related to taking psychoactive substances, depression, anxiety disorders of various aetiology, or sleep disorders of various aetiology, comprising adminstering to the subject the compound of claim 1 or a pharmaceutically acceptable salt thereof.

17. A pharmaceutical composition comprising a compound of formula (I) or a salt thereof as defined in claim 10 and at least one pharmaceutically acceptable excipient.

18. A pharmaceutical composition comprising a compound of formula (I) or a salt thereof as defined in claim 14 and at least one pharmaceutically acceptable excipient.

19. A method for treatment of a subject afflicted with Alzheimer's disease, Parkinson's disease, Lewy body dementia, dementia-related psychosis, schizophrenia, delusional syndromes and other psychotic conditions related and not related to taking psychoactive substances, depression, anxiety disorders of various aetiology, or sleep disorders of various aetiology, comprising adminstering to the subject the compound of claim 10 or a pharmaceutically acceptable salt thereof.

20. A method for treatment of a subject afflicted with Alzheimer's disease, Parkinson's disease, Lewy body dementia, dementia-related psychosis, schizophrenia, delusional syndromes and other psychotic conditions related and not related to taking psychoactive substances, depression, anxiety disorders of various aetiology, or sleep disorders of various aetiology, comprising adminstering to the subject the compound of claim 14 or a pharmaceutically acceptable salt thereof.